Reports Q2 revenue $47.4M, consensus $47.37M. “Our base revenue, which excludes revenue from high-volume CleanCap, grew 5% in the quarter, led by strong demand for our Cygnus products and services,” said Bernd Brust, CEO, Maravai LifeSciences (MRVI).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVI:
- Maravai Lifesciences Announces Major Organizational Restructuring
- Maravai Lifesciences Holdings, Inc. (MRVI) Q2 Earnings Cheat Sheet
- Strategic Leadership Changes and Financial Discipline Drive Buy Rating for Maravai Lifesciences Holdings
- Maravai Lifesciences Appoints New CFO Rajesh Asarpota
- Maravai Lifesciences CFO Kevin Herde to switch roles, Rajesh Asarpota to succeed